Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease
Why the study?
Do platelet glycoprotein IIb/IIIa inhibitors reduce death, myocardial infarction, and revascularization in patients with ischemic heart disease?
Population
32,135 patients from 16 randomized controlled trials with ischemic heart disease.
Comparison
Platelet glycoprotein IIb/IIIa inhibitors as a… vs Control group in randomized controlled trials
Design
Meta-analysis
Follow-up
up to 6 months
Authors
Discussion
Loading...
Member takes
Implication
Supports GP IIb/IIIa inhibitor use in ACS and PCI; confirms composite benefit across trials.
Key Points
- The study aims to assess the effect of glycoprotein IIb/IIIa receptor antagonists on clinical outcomes in ischemic heart disease.
- Conducted a systematic overview (meta-analysis) of 16 randomized controlled trials
- Included outcomes from 32,135 patients
- Calculated odds ratios (ORs) for various endpoints including mortality and myocardial infarction
- Significant reduction in mortality at 48 to 96 hours (OR 0.70, 95% CI 0.51 to 0.96, P<0.03)
- 30-day composite endpoint of death or MI improved (OR 0.76, 95% CI 0.66 to 0.87, P<0.001)
- Composite outcome of death, MI, or revascularization also showed significant benefit (OR 0.77, 95% CI 0.68 to 0.86, P<0.001)
Structured PICO
Do platelet glycoprotein IIb/IIIa inhibitors reduce death, myocardial infarction, and revascularization in patients with ischemic heart disease?
P
Population
32,135 patients from 16 randomized controlled trials with ischemic heart disease (therapeutic indications: percutaneous intervention or acute coronary syndromes).
I
Intervention
Platelet glycoprotein (GP) IIb/IIIa inhibitors as a class
C
Comparator
Control group in randomized controlled trials
O
Outcome
Death, myocardial infarction (MI), and revascularization at 48 to 96 hours, 30 days, and 6 monthshard clinical
GP IIb/IIIa inhibitors significantly reduce the composite of death or MI, as well as death, MI, or revascularization, in patients with ischemic heart disease undergoing percutaneous intervention or presenting with acute coronary syndromes.
Cite This Study
Kong et al. (1998) studied this question.